In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), with a price target of $20.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ram Selvaraju has given his Buy rating due to a combination of factors regarding Entrada Therapeutics Inc. The company’s lead candidate, ENTR-601-44, received regulatory clearance to commence a Phase 1/2 clinical trial in the UK for treating Duchenne muscular dystrophy, which is a significant milestone. Previous trials showed promising results, with no serious adverse events and a statistically significant level of exon skipping, suggesting a strong therapeutic potential.
Additionally, the valuation of Entrada Therapeutics is supported by a discounted cash flow analysis, estimating an enterprise value of approximately $511 million. With calculated probabilities of approval for their drug candidates, and a total firm value projected at $980 million, Selvaraju sees a favorable risk-reward balance for investors. However, potential risks such as regulatory challenges, unfavorable clinical data, and partnership uncertainties are also acknowledged.
In another report released yesterday, Roth MKM also reiterated a Buy rating on the stock with a $29.00 price target.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TRDA in relation to earlier this year.